drugset / Trial / NCT07286266
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
RandomizedParallel-groupSingle-blindTreatment
Summary
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating ovarian cancer compared to standard treatments. The study also assesses whether Mo-Rez is safe and tolerated well by participants compared to standard treatments and aims to provide a better understanding of the main side effects of the drug.
Timeline
- Start
- 2026-06-18
- Primary completion
- 2029-12-17
- Completion
- 2029-12-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | — | — |
| Comparator | Doxorubicin | Other / unclassified | — | — |
| Comparator | Gemcitabine | Small molecule | — | — |
| Subject | Mocertatug rezetecan | Unknown | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Comparator | Topotecan | Small molecule | — | — |